Navigation Links
First Patient Enrolled in SARcode Bioscience's Pivotal Dry Eye Study of SAR 1118 Ophthalmic Solution
Date:9/14/2011

BRISBANE, Calif., Sept. 14, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.  

(Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO)

SAR 1118 is a first-in-class molecule that inhibits T-cell inflammation by blocking the binding of two key cellular surface proteins (LFA-1 and ICAM-1) that mediate the chronic inflammatory cascade.  SAR 1118 may be able to reduce inflammation associated with dry eye disease.

The OPUS-1 trial will study the safety and efficacy of SAR 1118 in the treatment of dry eye disease.  Approximately 588 patients will be randomized to receive SAR 1118 5.0% ophthalmic solution or placebo twice daily over 12 weeks.  The co-primary endpoints of the study are corneal fluorescein staining score and visual-related function score (reading, driving at night, computer use, and watching television) as measured by the Ocular Surface Disease Index (OSDI), a validated instrument designed to assess the impact of dry eye upon vision-related activities.  The safety and tolerability of SAR 1118 compared to placebo at 12 weeks will also be evaluated.

"The OPUS-1 study aims to replicate the positive results observed in the Phase 2 dry eye trial, which demonstrated increases in tear production as early as 2 weeks, an improvement in corneal staining, and better visual-functional outcomes in the SAR 1118 treatment groups compared to placebo," said Charles Semba, MD, Chief Medical Officer. "Initiating patient enrollment in our Phase 3 trial is a significant milestone for SARcode Bioscience as we continue to progress towards our goal of making this therapy commercially available to millions of dry eye sufferers."

"Dry eye is an extremely common and significant problem encountered by eye care professionals," comm
'/>"/>

SOURCE SARcode Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that ... of Lixte,s lead compound, LB‑100, is being conducted, has been ... S. Kovach , M.D., the founder and President of Lixte, ... at a single site. Accrual of patients, however, was slower ...
(Date:1/23/2015)... DUBLIN , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... of Directors has approved a share repurchase program. The ... $300 million of Mallinckrodt plc ordinary shares. ... opportunities remain top priorities as we continue to pursue ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... DUBAI, UAE, February 8, 2012 In the ... diabetic; six countries in the MENA region are among the ... include the United Arab Emirates, Bahrain, Egypt, Kuwait, Oman and ... accounting for 14 percent of its total health care expenditure ...
... 7, 2012  Prometheus Laboratories Inc., a specialty pharmaceutical ... a research and collaboration agreement with an unnamed ... Prometheus, proprietary oncology diagnostic platform (CEER) to develop ... The CEER arrays may ultimately be used in ...
Cached Medicine Technology:Meeting of the Region's Top Diabetes Experts in Dubai this March 2Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company 2
(Date:1/22/2015)... 22, 2015 Woodloch Pines, an all-inclusive ... selected by TripAdvisor as the number one best large hotel ... in the world for their annual Travelers’ Choice Awards. ... . The website is home to millions of unbiased and ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... 2015 The federal court overseeing thousands of ... Court, Southern District of West Virginia has upheld a $2 ... first bellwether trial. In an Order dated January 21st, the ... finding that C.R. Bard had not proven a miscarriage of ...
(Date:1/22/2015)... 2015 Autocarinsurancebest.com has released a new blog ... auto insurance policy . , Auto insurance quotes help ... is no longer necessary to call an agent or visit ... online on a single website: http://autocarinsurancebest.com/ . , Every ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
Breaking Medicine News(10 mins):Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... back to the cancer communities in the cities visited ... Society for Therapeutic Radiology and Oncology (ASTRO) is partnering ... of cancer survivorship. The Kenneth B. Schwartz Center conducts ... the art of compassionate healthcare. , The Kenneth B. ...
... instances of Salmonella poisoning linked to a jalapeno pepper in Texas, ... sweating it out over the jalapeno crisis do not have to ... Resource reveals some fiery competition. , ... LENEXA, ...
... of articles and magazine covers talk about retirement, but the fact is ... By 2010, 58 million people--20% of the population--will be 50-64. ... survive and thrive in this challenging PreRetirement life stage? , ... (PRWEB) ...
... of Public Health Confirms Positive Review ... of DNA ... it received a formal letter from the California Department of Public,Health (CDPH) ... letter states that DNA Direct,s tests are,performed only with a physician order ...
... Inc. (Amex: ADK ), an Ohio based long ... refinancing of one of its nursing,homes in Ohio., ... single story nursing home,facility located in Greenfield, Ohio. Recently, ... of the art private bedrooms, along with a new,kitchen, ...
... Foundation to Provide Health Coverage Eligibility Screening and ... Application Assistance to Uninsured, ... wholly funded by WellPoint, Inc., has,awarded The CoverMe Foundation a ... in identifying and assisting uninsured persons,and families in finding and ...
Cached Medicine News:Health News: No More Jalapenos? No Problemo! Salmonella-Free Alternatives : No More Jalapenos? No Problemo, yes Poblano! 2Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 2Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 3Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 4Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 5Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 6Health News:Surviving Your PreRetirement Years: 15 Things You Must Do Between 50 and 64 7Health News:DNA Direct Confirms It Is Operating in Compliance with California State Laboratory Law 2Health News:AdCare Health Systems, Inc. Announces the Refinancing of a Nursing Home in Ohio 2Health News:WellPoint Foundation Awards $2.5 Million Grant to The CoverMe Foundation 2Health News:WellPoint Foundation Awards $2.5 Million Grant to The CoverMe Foundation 3
... of the outstanding features of our Neomax ... Molding Technology. , This manufacturing process allows ... controls the bunching and irritation in the ... wearer. , ,Colors available: Blue, ...
... Flex™ might just be the world's most ... functional support, post-op/rehab support, or both, Flex ... new Accutrac™ ROM hinges control flexion and ... long-term durability while being heat-moldable to accommodate ...
... Donut is a neoprene alternative, constructed ... polyester Lycra Fabric that allows for ... provides for patellar control. Ideal for ... or irritations. Click here to view ...
... of the TROM provides the same easy ... as the full foam TROM, but is ... of use and versatility of the Cool ... following major ligament surgery, meniscal repairs, patella ...
Medicine Products: